Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4
3(60.0%)
N/A
2(40.0%)
5Total
Phase 4(3)
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07528820Not ApplicableNot Yet Recruiting

Inflammatory Profiles, Histopathological Features, and Remodeling Factors in Chronic Rhinosinusitis With Nasal Polyps

Role: lead

NCT05642806Phase 4Recruiting

Comparison of Immune Profiles in Chronic Rhinosinusitis Patients After Mepolizumab Treatment

Role: lead

NCT06107101Phase 4Not Yet Recruiting

th2 Modulation CRSwNP

Role: lead

NCT04601324Phase 4Withdrawn

Allergic Rhinitis Combination Pharmacotherapy Efficacy Study

Role: lead

NCT04374448Not ApplicableUnknown

Utility of Indocyanine Green Fluorescence in Endoscopic Sinonasal and Skull Base Surgery

Role: lead

All 5 trials loaded